Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Temelimab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms RAINBOW-T1D
- Sponsors GeNeuro Australia
- 20 Dec 2018 According to a GeNeuro media release, final 12- month results from this study is anticipated in the second quarter of 2019.
- 24 Oct 2018 According to a GeNeuro media release, the study met its primary endpoint of safety in this new patient population.
- 20 Sep 2018 According to a GeNeuro media release, final visit of the last patient is expected by the end of 2018.